

CITATION REPORT

List of articles citing

Rhabdomyolysis induced by rosuvastatin and sildenafil

DOI: 10.1097/smj.ob013e3181foe89c
Southern Medical Journal, 2010, 103, 1052-4.

Source: <https://exaly.com/paper-pdf/47655486/citation-report.pdf>

Version: 2024-04-18

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
10	First reports of serious adverse drug reactions in recent weeks. <i>Drugs and Therapy Perspectives</i> , 2011 , 27, 21-22	1.5	
9	Statin-induced myopathies. <i>Pharmacological Reports</i> , 2011 , 63, 859-66	3.9	109
8	Rosuvastatin suppresses the liver microsomal CYP2C11 and CYP2C6 expression in male Wistar rats. <i>Xenobiotica</i> , 2012 , 42, 731-6	2	13
7	Atorvastatin improves erectile dysfunction in patients initially irresponsive to Sildenafil by the activation of endothelial nitric oxide synthase. <i>International Journal of Impotence Research</i> , 2013 , 25, 143-8	2.3	30
6	Sildenafil overdose can cause rhabdomyolysis and subjective visual perception changes. <i>Nephrology</i> , 2014 , 19, 258	2.2	11
5	Simultaneous determination of rosuvastatin, naringin and naringenin in rat plasma by RRLC-MS/MS and its application to a pharmacokinetic drug interaction study. <i>Journal of Chromatographic Science</i> , 2018 , 56, 611-618	1.4	9
4	Atorvastatin and sildenafil interaction-induced rhabdomyolysis. <i>Annals of Pharmacotherapy</i> , 2020 , 54, 1047-1048	2.9	3
3	A Rare Cause of Rhabdomyolysis:Sildenafil. <i>Journal of Emergency Medicine Case Reports</i> , 2019 , 10, 98-100.		0
2	Prevalence and predictors of clinically significant statin-drug interactions among Yemeni patients taking statins for primary and secondary prevention of cardiovascular disease.. <i>Current Medical Research and Opinion</i> , 2022 , 1-27	2.5	
1	Statins synergize with phosphodiesterase type 5 inhibitors but not with selective estrogen receptor modulators to prevent myofibroblast transformation in an in vitro model of Peyronie's disease.		0